"...Lipscombe said he is confident of an imminent deal with SHL, despite facing several key deadline extensions.
“That deal is very close, and we’ve been working on that for two or three years now and from an operational perspective everything is full steam ahead,” he said.“We do have to finish the paperwork and get that agreement signed and that has been imminent for the last few weeks so we’re hoping to be able to talk more about that in the next week or so.”
Morgans has a speculative buy on PIQ with a target price of $1.77. Healthcare research analyst Iaian Wilkie told St**khead the key near-term catalyst of a distribution deal with Sonic Healthcare USA for PromarkerD has a high likelihood of success, and is close to being finalised.
"We see confirmation would likely result in a rapid rerate of the share price with the key determining factor being the level of detail able to be provided to balance continuous disclosure requirements versus commercial in confidence detail,” he said.“Our confidence continues despite several key term deadline extensions, backed by ongoing featuring of the test on SHUSA’s marketing material, the granting of US regulatory access protocols (filing joint PLA code for reimbursement), and our view that there is little reason to request continual extension of contract deadlines if its interest was declining.”
Let's all hope so.
PIQ Price at posting:
99.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)